Feline Hypertrophic Cardiomyopathy: Screening and Management

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Feline hypertrophic cardiomyopathy (HCM) is the most common acquired cardiac disease in cats, affecting up to 15% of the population, though severe outcomes like heart failure or arterial thromboembolism occur in a minority. Screening is indicated for cats with murmurs, gallops, arrhythmias, breed predispositions, or a history of thromboembolism.
• Two-dimensional echocardiography with Doppler is the diagnostic standard for HCM, assessing left ventricular wall thickness and left atrial size. Mild to moderate thickening requires ruling out secondary causes such as hyperthyroidism, systemic hypertension, and acromegaly.
• Left atrial enlargement, quantified by the left atrial-to-aortic ratio (mean ratio of 2.08 in affected cats), is the dominant risk factor for arterial thromboembolism and heart failure, guiding risk stratification and monitoring intervals.
• Dynamic left ventricular outflow tract (LVOT) obstruction, often due to systolic anterior motion of the mitral valve, is present in approximately two-thirds of HCM cats and influences drug selection; atenolol is the preferred agent for this condition.
• Antithrombotic therapy, primarily with clopidogrel, is recommended for cats with left atrial enlargement, spontaneous echocardiographic contrast, or a prior thromboembolic event to reduce recurrence risk, though no agent completely prevents it.
• Monitoring involves serial echocardiography to track wall thickness and left atrial size, alongside annual reassessment of blood pressure and thyroid status in older cats, with specific intervals based on disease severity and presence of left atrial enlargement.

Feline hypertrophic cardiomyopathy (HCM) is the most common acquired cardiac disease in domestic cats, with an estimated prevalence approaching 15% of the general population, though severe disease with heart failure or arterial thromboembolism develops in only a minority of affected animals Kittleson and Côté, feline cardiomyopathy review. This article provides a diagnostic-reasoning framework for the practicing veterinarian, covering screening strategies, echocardiographic assessment, drug selection for long-term management, and thromboembolism prevention. Emergency treatment of congestive heart failure and acute arterial thromboembolism is excluded, the focus is on stable, ambulatory patients.

The clinical question this article answers is practical: which cats should be screened, how should equivocal echocardiographic findings be interpreted, and what monitoring parameters guide therapeutic decisions once HCM is confirmed? The evidence base draws on peer-reviewed studies of feline cardiomyopathy, consensus guidance from the American College of Veterinary Internal Medicine, and standard professional references ACVIM consensus statements, MSD Veterinary Manual. Where the literature is limited or contested, this is stated explicitly.

At a Glance

Epidemiology and Natural History

HCM affects domestic cats of any age from three months upward, with a higher reported prevalence in males and domestic shorthairs Kittleson and Côté, feline cardiomyopathy review. The disease is typically subclinical, and many affected cats live for years without clinical signs. Severe outcomes, specifically congestive heart failure and arterial thromboembolism, occur in a small proportion of the affected population.

Congenital heart disease is uncommon in cats, with a prevalence of 0.14% in a large mixed-breed population, and ventricular septal defects, aortic stenosis, and hypertrophic obstructive cardiomyopathy were the most common lesions identified Schrope, congenital heart disease prevalence. This distinction matters clinically: a young cat with a murmur is far more likely to have HCM than a congenital defect, but the possibility of structural congenital disease should not be dismissed without echocardiography.

Pathophysiology and Phenotypic Spectrum

The primary defect in HCM is impaired diastolic relaxation and increased myocardial stiffness, leading to elevated left ventricular filling pressures. The left ventricular cavity is typically small, and wall thickening may be diffuse, involving the septum and free wall, or segmental, with the anterior septum most commonly affected Fox et al., echocardiographic assessment. Asymmetrical thickening is more common than concentric hypertrophy.

Systolic anterior motion of the mitral valve produces dynamic left ventricular outflow tract obstruction in a substantial proportion of affected cats, with Doppler-estimated gradients ranging from 25 to 110 mm Hg in one series Fox et al., echocardiographic assessment. The presence and severity of obstruction influence drug selection, as discussed in the management section of this article.

Left Atrial Enlargement as a Prognostic Marker

Left atrial size reflects the hemodynamic burden of diastolic dysfunction and is the most clinically useful predictor of adverse outcomes. Cats that died with heart failure had greater left ventricular wall thickness than survivors in an early echocardiographic study Fox et al., echocardiographic assessment. Left atrial enlargement is also the dominant risk factor for arterial thromboembolism, in a retrospective series of 100 cats with distal aortic thromboembolism, the mean left atrial-to-aortic ratio was 2.08 Laste and Harpster, thromboembolism retrospective.

Measurement Technique and Methodological Caution

Left atrial size can be assessed using M-mode or two-dimensional echocardiography, and the methods do not agree perfectly. The left atrial dimension from 2D short-axis images indexed to aortic diameter is generally smaller than the analogous M-mode index, while the 2D long-axis index tends to be larger Abbott and MacLean, left atrial assessment. Clinicians should use a consistent measurement technique and apply reference intervals appropriate to that method, instead of mixing approaches across serial examinations.

Diagnostic Reasoning in Screening

Screening for HCM is indicated in cats with auscultatory abnormalities, in breeds with known or suspected genetic predisposition, and in cats being evaluated for thromboembolic events. A heart murmur or gallop sound may be present, but their absence does not exclude disease Kittleson and Côté, feline cardiomyopathy review. Biomarkers such as NT-proBNP should not be relied upon as a sole diagnostic test.

Severe HCM is usually diagnosable by echocardiography alone. Mild to moderate left ventricular wall thickening, however, is a diagnosis of exclusion: hyperthyroidism, systemic hypertension, acromegaly, and dehydration can all produce secondary hypertrophy that mimics HCM Kittleson and Côté, feline cardiomyopathy review. A minimum database including total thyroxine, systolic blood pressure, and hydration assessment is therefore required before committing a cat with equivocal thickening to a lifelong diagnosis of HCM.

Genetic Considerations

A genetic cause of HCM has been identified in two breeds and is suspected in another, but for most cats the underlying etiology remains unknown Kittleson and Côté, feline cardiomyopathy review. Genetic testing is not yet a substitute for echocardiographic screening in the general population. Breed-specific testing programs exist for some predisposed breeds, and veterinarians should consult current breed club and genetic testing laboratory guidance for the specific breeds they encounter.

Screening Protocol and Diagnostic Sequence

Screening for feline hypertrophic cardiomyopathy (HCM) begins with signalment, history, and physical examination. Male cats and domestic shorthair cats are overrepresented, and disease can appear from three months of age onward. Feline cardiomyopathies: hypertrophic cardiomyopathy notes that subclinical disease may affect up to approximately 15% of the domestic cat population. A heart murmur or gallop sound may be present, but their absence does not exclude HCM.

Auscultation findings guide the next step. A soft systolic murmur over the left apex or sternal border raises suspicion for dynamic outflow obstruction or mitral regurgitation. An arrhythmia, particularly in a cat with no other explanation, warrants echocardiography. However, the absence of both murmur and gallop does not lower pretest probability in a high-risk breed or in a cat with a family history.

Point-of-care biomarkers, including N-terminal pro-B-type natriuretic peptide, can support clinical suspicion but should not be used alone to establish the diagnosis. Feline cardiomyopathies: hypertrophic cardiomyopathy explicitly advises against relying solely on biomarkers. A normal biomarker result in a cat with a murmur does not rule out structural disease, and an elevated result in a cat with renal disease or dehydration may be falsely reassuring in the opposite direction.

The screening echocardiogram should be performed with the cat gently restrained in lateral recumbency, with minimal chemical restraint unless the cat is fractious. Sedation can lower heart rate and alter loading conditions, which may reduce the severity of dynamic outflow obstruction. If sedation is required, the clinician should record the agent used and interpret wall thickness and obstruction accordingly.

Echocardiographic Decision Points

Two-dimensional echocardiography from the right parasternal long-axis view provides the most reliable assessment of left ventricular wall thickness. Measure the interventricular septum and left ventricular free wall at end-diastole, using the leading-edge technique, and compare them against published reference intervals for the ultrasound machine and species. Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy documented that wall thickening in affected cats is most often diffuse, involving both septum and free wall, but can be segmental, including thickening confined to the anterior septum. A single normal measurement in one view does not exclude segmental disease.

Mild to moderate thickening presents a diagnostic challenge. Feline cardiomyopathies: hypertrophic cardiomyopathy describes HCM with mild to moderate left ventricular wall thickening as a diagnosis of exclusion. Hyperthyroidism, systemic hypertension, acromegaly, and dehydration can each produce secondary hypertrophy. In an older cat with borderline wall thickness, measure systemic blood pressure and serum total thyroxine before assigning a primary HCM diagnosis. In a young cat with no identifiable cause, repeat echocardiography in six to twelve months may clarify progression.

Left atrial size is the single most important prognostic measurement obtained during screening. The left atrial-to-aortic root ratio from the right parasternal short-axis view, using either M-mode or two-dimensional imaging, stratifies risk. Two-dimensional echocardiographic assessment of the feline left atrium demonstrated that two-dimensional indices generally differ from M-mode indices, with a mean bias of -0.13 for the short-axis ratio. Use one method consistently for serial comparisons and record the method in the medical record.

Systolic anterior motion of the mitral valve should be actively sought in every study. It is present in roughly two-thirds of affected cats and produces dynamic left ventricular outflow tract obstruction. Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy reported Doppler-estimated gradients of 25 to 110 mm Hg in cats with marked systolic anterior motion. Continuous-wave Doppler through the left ventricular outflow tract from the apical or subcostal window quantifies the gradient, but the value varies with heart rate, volume status, and sedation.

Risk Stratification and Screening Intervals

Cats with normal echocardiographic findings and no murmur can be rescreened in twelve to twenty-four months, depending on breed and family history. Cats with mild hypertrophy and normal left atrial size should be rescreened in six to twelve months. Cats with moderate to severe hypertrophy, left atrial enlargement, or a history of syncope warrant rescreening in three to six months, and the owner should be counseled on monitoring for tachypnea, lethargy, and hindlimb paresis.

Left atrial enlargement is the dominant risk factor for arterial thromboembolism. A retrospective study of 100 cases of feline distal aortic thromboembolism found a mean left atrial-to-aortic ratio of 2.08 in affected cats, with hypertrophic cardiomyopathy as the underlying disease in 58% of cases. A ratio above 2.0 should trigger discussion of thromboembolism prophylaxis and closer monitoring, even in an otherwise asymptomatic cat.

Medical Management of Subclinical Disease

No drug has been shown to alter the progression of myocardial hypertrophy in feline HCM. Beta-blockers and calcium channel blockers reduce heart rate and improve diastolic filling in some cats, but neither class has demonstrated a survival benefit in prospective trials. The decision to treat a subclinical cat should therefore target a specific hemodynamic abnormality instead of the diagnosis itself.

Atenolol is the preferred agent when systolic anterior motion and dynamic outflow obstruction are present. It reduces heart rate, prolongs diastolic filling time, and decreases myocardial oxygen demand. A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy demonstrated that direct reduction of contractility relieves outflow obstruction, supporting the rationale for negative inotropic therapy, although the study evaluated an investigational agent not available clinically. Diltiazem may be considered when diastolic dysfunction predominates without significant obstruction, but it has less effect on outflow gradients. Current formulary and label references must be consulted for dosing, and heart rate should be reassessed two weeks after initiation.

Thromboembolism Prevention

Cats with left atrial enlargement, spontaneous echocardiographic contrast, or a previous thromboembolic event are candidates for antithrombotic therapy. The evidence base for specific agents in cats is limited, and no drug completely prevents recurrence. A retrospective study of 100 cases of feline distal aortic thromboembolism reported an average long-term survival of 11.5 months in the 37% of cats that survived the initial episode, underscoring the guarded prognosis and the importance of owner communication.

Clopidogrel is the most commonly recommended agent for thromboembolism prevention in cats with HCM and left atrial enlargement. Aspirin is a less potent alternative. The choice between them should account for owner compliance, cost, and the cat's tolerance of daily oral medication. Cats with a prior thromboembolic event warrant lifelong therapy, and the owner should be counseled on the signs of recurrent thrombosis, including acute hindlimb paresis, vocalization, and pain.

Monitoring and Documentation

Serial echocardiography should track wall thickness, left atrial size, and outflow gradient using identical imaging planes and measurement techniques. Blood pressure and serum thyroxine should be reassessed at least annually in older cats to exclude acquired causes of hypertrophy. Heart rate and rhythm should be documented at each visit, and Holter monitoring is indicated if syncope or suspected arrhythmias are reported.

The medical record should include the echocardiographic views obtained, the measurement method for left atrial size, the presence or absence of systolic anterior motion, and the Doppler gradient when obstruction is identified. This documentation allows meaningful comparison across visits and between clinicians. When findings are equivocal, a second echocardiogram by a cardiologist or experienced ultrasonographer is appropriate before committing a cat to long-term therapy.

Recognized Complications and Early Detection

The principal complications of feline HCM are congestive heart failure, arterial thromboembolism (ATE), and sudden death. Each has identifiable precursors that screening should capture before clinical decompensation occurs.

Left atrial enlargement is the strongest echocardiographic predictor of both heart failure and ATE. In a retrospective series of 100 cats with distal aortic thromboembolism, the mean left atrial-to-aortic ratio was 2.08, and hypertrophic cardiomyopathy was the underlying diagnosis in 58% of cases Laste and Harpster, retrospective study of feline distal aortic thromboembolism. Serial measurement of the left atrial-to-aortic ratio using a consistent technique therefore forms the backbone of monitoring. A ratio that rises across visits, even while still below the heart failure threshold, should prompt more frequent reassessment and a review of owner compliance with medication.

Dynamic left ventricular outflow tract obstruction develops in roughly two-thirds of affected cats and is associated with a higher risk of disease complications Stern et al, small molecule inhibitor study in feline HCM. Systolic anterior motion of the mitral valve is the usual mechanism. Detection requires careful interrogation of the left ventricular outflow tract with color and spectral Doppler, because the obstruction is often labile and may be absent at rest. Provocative maneuves such as gentle handling or dobutamine challenge are not standardized in cats and are not recommended for routine screening.

Sudden death occurs without reliable warning signs in some cats. The presence of syncope, documented ventricular arrhythmias, or severe left ventricular hypertrophy with a small cavity should raise concern, but the absence of these findings does not confer safety.

Common Errors and Corrective Action

Less experienced operators frequently misclassify mild wall thickening as definitive HCM. Feline HCM with mild to moderate left ventricular wall thickening is a diagnosis of exclusion, and hyperthyroidism, systemic hypertension, acromegaly, and dehydration must be ruled out before committing to the diagnosis Kittleson and Côté, feline cardiomyopathies review. A single borderline measurement should never be reported as HCM without a full systemic workup.

A second recurring error is reliance on M-mode left atrial measurement alone. Two-dimensional indices from short-axis and long-axis planes do not agree perfectly with M-mode values, and the discrepancy is clinically relevant across the range of atrial sizes seen in HCM Abbott and MacLean, two-dimensional echocardiographic assessment of the feline left atrium. The operator should choose one method, document it in the record, and use the same method at every recheck.

A third error is treating every murmur as HCM. Innocent murmurs occur in approximately 0.16% of mixed-breed cats, and dynamic outflow obstruction can mimic a structural murmur Schrope, prevalence of congenital heart disease in mixed-breed cats. Echocardiography remains the only reliable discriminator, and biomarkers should not be used alone to establish the diagnosis Kittleson and Côté, feline cardiomyopathies review.

Limitations of the Evidence

The evidence base for feline HCM management rests heavily on retrospective studies and expert opinion. Prospective randomised trials comparing treatment strategies are scarce, and most drug recommendations are extrapolated from human cardiology or from small feline cohorts. The ACVIM consensus statements provide structured guidance but explicitly acknowledge areas where data are insufficient ACVIM consensus statements.

Expert opinion still differs on several points. The threshold for starting beta-blockade in cats with dynamic outflow obstruction but no clinical signs is not universally agreed. Whether early intervention alters the natural history of subclinical disease remains unknown. The role of novel sarcomere inhibitors, which acutely relieve outflow tract obstruction in experimental feline HCM, is promising but not yet established in clinical practice Stern et al, small molecule inhibitor study in feline HCM.

When to Refer

Referral to a veterinary cardiologist is warranted when the diagnosis is uncertain, when the echocardiographic study is technically challenging, or when the owner is considering treatment decisions that depend on precise risk stratification. Cats with severe left atrial enlargement, recurrent syncope, or documented ATE should be managed in collaboration with a specialist where one is available.

Laboratory involvement is indicated when secondary causes of myocardial thickening are suspected. Thyroid hormone measurement, blood pressure assessment, and insulin-like growth factor testing for acromegaly should be performed before labeling a cat with idiopathic HCM MSD Veterinary Manual.

Regulatory reporting is rarely relevant to feline HCM. Breeders may request genetic testing or screening results for breeding decisions, and the veterinarian should present the limitations of such testing honestly. Where a cat is insured or where a legal dispute arises over a sale, contemporaneous records of the echocardiographic findings and the measurement technique used become important documentation.

Frequently Asked Questions

How Should I Screen for HCM When Referral Echocardiography Is Not Available?

When board-certified cardiology referral is unavailable, screening relies on a combination of physical examination, thoracic radiography, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) testing. A heart murmur, gallop sound, or arrhythmia increases suspicion, but their absence does not exclude disease. Radiographic left atrial enlargement supports advanced disease, while a normal cardiac silhouette does not rule out mild HCM. NT-proBNP has good negative predictive value for severe disease but should not be used alone for diagnosis, as the feline cardiomyopathies review emphasizes. If echocardiography is truly unavailable, document the screening limitations clearly, recommend serial rechecks, and refer when clinical signs or biomarker trends suggest progression.

What Is the Minimum Echocardiographic Protocol for Reliable HCM Screening?

A focused study should include right parasternal long-axis and short-axis views. Measure left ventricular free wall and interventricular septal thickness in diastole from the short-axis view at papillary muscle level. Assess the left atrium using the left atrial-to-aortic root ratio from both two-dimensional and M-mode images, recognizing that two-dimensional indices generally read lower than M-mode equivalents. Evaluate for systolic anterior motion of the mitral valve, left atrial enlargement, and pericardial effusion. Record a Doppler interrogation of the left ventricular outflow tract when dynamic obstruction is suspected. If image quality limits wall thickness measurement, state this in the record and schedule a repeat study instead of assigning a false-negative result.

How Do I Distinguish Physiological Wall Thickening from Mild HCM?

Mild left ventricular hypertrophy is a diagnosis of exclusion. Rule out hyperthyroidism, systemic hypertension, acromegaly, and dehydration before attributing wall thickening to HCM, as the feline cardiomyopathies review advises. Measure blood pressure in every cat with suspected HCM, and assess thyroid status in older cats. Physiological hypertrophy from athletic conditioning is uncommon in indoor cats but should be considered in outdoor or breeding animals. Serial echocardiography over three to six months can clarify the diagnosis: HCM tends to progress or remain stable, whereas reversible causes improve with treatment of the underlying condition. Document the differential list and the diagnostic plan in the medical record.

Which Drug Should I Choose First for a Cat with Dynamic Left Ventricular Outflow Obstruction?

Atenolol is the conventional first choice for cats with systolic anterior motion and measurable outflow tract obstruction. Beta-blockade reduces heart rate, improves diastolic filling, and decreases myocardial oxygen demand. Diltiazem is preferred when left atrial enlargement and diastolic dysfunction dominate without significant obstruction, because it improves relaxation and reduces afterload. The evidence base for comparing these drugs in cats is limited, and current ACVIM consensus statements provide the most useful framework for decision-making. Recheck echocardiography four to six weeks after starting therapy to assess whether obstruction has decreased and whether left atrial size has stabilized.

How Should I Discuss Thromboembolism Risk with an Owner?

Explain that arterial thromboembolism is a devastating complication of HCM, most strongly predicted by severe left atrial enlargement. Historical data show that cats with distal aortic thromboembolism have a mean left atrial-to-aortic ratio of approximately 2.08, and many have no prior cardiac diagnosis, as a retrospective study of 100 cases reports. Discuss the goals of antithrombotic therapy as risk reduction instead of elimination, and acknowledge that no drug guarantees prevention. Review the clinical signs of thromboembolism, including hindlimb paresis, vocalisation, and pain, so owners can seek immediate care. Document the discussion, the owner's decision, and the planned recheck interval in the record.

What Monitoring Schedule Should I Recommend for a Cat with Stable Subclinical HCM?

For cats with mild disease and no left atrial enlargement, recheck echocardiography every 12 months is reasonable. Cats with moderate to severe hypertrophy, left atrial enlargement, or a history of dynamic obstruction warrant rechecks every six months. At each visit, repeat blood pressure measurement, auscultation, and echocardiography. NT-proBNP can be measured between echocardiograms if clinical signs develop. Advise owners to seek prompt evaluation for tachypnoea, lethargy, or hindlimb weakness, as these may signal progression to congestive heart failure or thromboembolism. The MSD Veterinary Manual provides additional guidance on monitoring parameters and when to adjust therapy.

Related Clinical & Scientific Guides

• Feline Hepatic Lipidosis: Nutritional and Medical Management
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Respiratory Virus: Diagnostic and Management Considerations

References and Further Reading

• Prevalence of congenital heart disease in 76,301 mixed-breed dogs and 57,025 mixed-breed cats.. 2015.
• The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy.. 2021.
• Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy. An animal model of human disease.. 1995.
• Two-dimensional echocardiographic assessment of the feline left atrium.. 2006.
• A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy.. 2016.
• A retrospective study of 100 cases of feline distal aortic thromboembolism: 1977-1993.. 1995.
• ACVIM Consensus Statements. Journal of Veterinary Internal Medicine.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Feline Systemic Hypertension: Screening and Management
• Feline Cardiomyopathy: Phenotype Differentiation and Treatment
• Feline Urethral Obstruction: Emergency Management and Prevention
• Feline Chronic Enteropathy: Diagnostic and Management Framework
• Feline Hepatic Lipidosis: Nutritional and Medical Management

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.